Professor, Pathology, USC School of Medicine
Pathology
Dr. Michael F. Press, MD
|
|
Give Review
Dr. Michael F. Press practices Pathology. He went to University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine has a rank of 10 in research and a 19 in primary care Doctor Michael F. Press, MD is a published doctor and has 70 publications published. The lastest was: 'Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.' Doctor Michael F. Press, MD accepts all Medicare patients.
Publications
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroe...
- Many private mutations originate from the first few divisions of a human colorectal adenoma.
- A Big Bang model of human colorectal tumor growth.
- Reply to E.A. Rakha et al.
- PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance.
- Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.
- Genome-wide Scan of 29,141 African Americans Finds No Evidence of Directional Selection since Admixture.
- HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
- Meta-analysis of loci associated with age at natural menopause in African-American women.
- Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical ...
- A conceptual and methodological framework for investigating etiologic heterogeneity.
- Genome-wide association study of age at menarche in African-American women.
- A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry.
- A Genome-Wide Scan for Breast Cancer Risk Haplotypes among African American Women.
- Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BC...
- A genome-wide association study of breast cancer in women of African ancestry.
- Potential Utility of an Expression Array Signature for Predicting Anthracycline Responsiveness or Resistance.
- Correction: identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry.
- Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry.
- Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans.
- Obesity and Survival Among Black Women and White Women 35 to 64 Years of Age at Diagnosis With Invasive Breast Cancer.
- Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.
- Pathological characteristics of BRCA-associated breast cancers in Hispanics.
- Enhanced Statistical Tests for GWAS in Admixed Populations: Assessment using African Americans from CARe and a Breast Cancer Consortium.
- Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
- Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HE...
- Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.
- A case-control study of body mass index and breast cancer risk in white and African-American women.
- Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel i...
- Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.
- Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
- Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
- An admixture scan in 1,484 African American women with breast cancer.
- Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib i...
- Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports?
- Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women.
- Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
- Admixture mapping of 15,280 African Americans identifies obesity susceptibility loci on chromosomes 5 and X.
- Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.
- A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
- Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer.
- Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
- HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
- Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study.
- Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women.
- Timing of menarche and first full-term birth in relation to breast cancer risk.
- A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans.
- How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?
- Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
- Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study.
- Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer.
- Lifetime recreational exercise activity and breast cancer risk among black women and white women.
- Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical tr...
- Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
- Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
- Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
- Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
- Identification of TP53 mutations in human cancers using oligonucleotide microarrays.
- Lifetime recreational exercise activity and risk of breast carcinoma in situ.
- Antibody-mediated targeting of replication-competent retroviral vectors.
- P7 antigen expression in human breast cancer.
- Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer speci...
- The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results.
- Characterization of HER2 Status by Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC).
- Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
- Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia.
- Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
University of Chicago
Doctors Specialties
- Anatomic Pathology
- Pathology
Accepted Insurances
Education
-
University of Chicago -
University of Chicago Pritzker School of Medicine
Hospital
-
Keck Hospital of USC
Helpful Reviews
Similar Doctors
|
|
Dr. Chi Lai, MD |
|
|
Dr. Joseph A. Dubeau, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michael N. Koss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Avram A. Jacobson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laurence J. Purdy, MD |
|
|
Dr. John P. Nachazel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hyun Y. Pak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lidija M. Petrovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven R. McLaren, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nick M. Shillingford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason P. Tovar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan W. Said, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Hongbin D. Zha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Y. Lu, MD |